Agoracom Blog Home

Posts Tagged ‘small caps’

Quantum BioPharma Cuts Liabilities in Half, Boosts Equity 275%, and Strengthens Path to Phase 2 MS Trial

Posted by Brittany McNabb at 12:09 PM on Tuesday, November 11th, 2025

Quantum BioPharma Ltd. (NASDAQ/CSE: QNTM; FRA: 0K91) today reported a strong third quarter, marking continued progress across both financial and scientific fronts. The biopharmaceutical company, focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol-related conditions, demonstrated clear operational discipline while advancing its clinical and consumer health initiatives.

Financial Turnaround Anchored by Balance-Sheet Strength

Quantum BioPharma delivered significant quarter-over-quarter improvement, underscoring the company’s strengthened financial foundation. Shareholder equity increased 275%, while the debt-to-equity ratio improved by 86%, driven largely by the full elimination of liabilities related to previously issued convertible debentures.

Total liabilities declined from US $13.2 million to US $6.6 million, and general and administrative expenses were reduced by 8%. Liquidity improved substantially, with the current ratio rising to 1.41x from 0.78x in the prior quarter. Collectively, these results reaffirm the company’s “no going concern” position and extend its cash runway beyond March 2027.

Quantum also realized US $572,000 in gains from its digital-asset portfolio, primarily Bitcoin, as part of a diversified treasury strategy. As of September 30, 2025, the company held US $5.2 million in digital assets, up from US $0.8 million at year-end 2024, further enhancing its financial flexibility.

Lucid-MS: Advancing a New Approach to Multiple Sclerosis

At the core of Quantum’s R&D pipeline is Lucid-21-302 (Lucid-MS), a patented, first-in-class oral drug candidate designed to target the underlying biology of demyelination — the process that drives nerve-fiber damage in Multiple Sclerosis (MS).

The company recently completed 3- and 6-month oral toxicity studies that showed no toxicity or adverse side effects, a key milestone supporting advancement toward a Phase 2 human efficacy trial. Lucid-MS’s oral formulation offers a convenient alternative to existing MS therapies that require injections or infusions.

Quantum has also partnered with Massachusetts General Hospital (MGH) researchers in a joint PET imaging study to validate a new approach for monitoring myelin integrity in MS patients. In parallel, the company has engaged a global pharmaceutical development organization to prepare an Investigational New Drug (IND) submission to the U.S. FDA.

“Lucid-MS represents a new direction in MS treatment — one focused on protecting myelin and addressing the biological drivers of neurodegeneration,” said Zeeshan Saeed, President and Chief Executive Officer.

Expanding Consumer Health and Diversified Assets

Beyond its pharmaceutical programs, Quantum continues to expand its portfolio of commercially active consumer health assets.

Its licensed product unbuzzd™, designed to accelerate alcohol metabolism and ease hangover symptoms, is marketed in the United States by Unbuzzd Wellness Inc. The licensee launched powder stick packs in late 2024 and has since initiated a Reg D  financing of up to US $5 million in preparation for a potential initial public offering — without any equity dilution to Quantum.

In Canada, Health Canada has granted a Product License for Qlarity™, a natural-health formulation that supports energy, metabolism, and cognitive performance. Qlarity™ complements Quantum’s broader focus on neurological health and wellness.

Sustained Progress and Long-Term Vision

The third quarter also saw continued progress in Quantum’s efforts to address alleged market manipulation of its stock. Management confirmed that all hedge-fund-held warrants have now expired, and that a special dividend of Contingent Value Rights (CVRs) was distributed to Class B shareholders in October 2025.

Looking ahead, Quantum BioPharma plans to maintain disciplined financial management while advancing its clinical and consumer-health milestones. The company’s balance-sheet strength, diversified portfolio, and advancing MS program collectively establish a foundation for sustained growth in 2026 and beyond.

With a Phase 2 trial for Lucid-MS approaching and a global consumer-health pipeline expanding, Quantum BioPharma remains positioned at the intersection of biotechnology innovation, financial resilience, and long-term therapeutic impact.

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From 363K oz Gold to 413M lbs Nickel — Renforth Resources Powers Ahead with Dual-Track Growth Strategy

Posted by Brittany McNabb at 11:56 AM on Tuesday, November 11th, 2025

From 363K oz Gold to 413M lbs Nickel — Renforth Resources Powers Ahead with Dual-Track Growth Strategy

Renforth Resources Inc. (CSE: RFR; OTCQB: RFHRF; FSE: 9RR) continues to advance its dual focus on gold and critical minerals in Quebec’s Abitibi mining district — one of the world’s most prolific and infrastructure-rich jurisdictions. With 100% ownership of both the Parbec Gold Deposit and the Victoria Nickel-Polymetallic System, Renforth is strategically positioned at the intersection of two enduring global trends: gold’s role as a store of value and the accelerating demand for energy-transition metals such as nickel, copper, and cobalt.

Parbec Gold Deposit: Surface Work Strengthens Geological Model

Renforth recently completed a successful stripping program at the Parbec Gold Deposit, located adjacent to Agnico Eagle’s Canadian Malartic Mine. Covering approximately 2,200 square metres within the open-pit design area, the campaign marked the company’s first large-scale surface exposure program at Parbec.

Field crews identified several previously unrecognized faults and structural features intersecting the Cadillac Break — a prolific, gold-bearing corridor responsible for millions of ounces of historical production across the Abitibi. Visual observations and sampling confirmed lithologies previously observed only in drill core. These discoveries reinforce Renforth’s interpretation of Parbec as a structurally complex, open-ended system with meaningful near-surface potential.

While cold weather limited full channel sampling, grab samples were collected and dispatched for assay. Additional trenching, mapping, and sampling are planned for spring. This fieldwork supports Parbec’s updated 2025 mineral resource estimate of approximately 363,000 ounces of gold, representing a 29% increase from prior estimates, with 87% of ounces contained within an optimized open-pit shell.

Victoria Nickel-Polymetallic System: NI 43-101 Technical Report Filed

Renforth also filed its NI 43-101 Technical Report for the Malartic Metals Package, including the maiden Inferred Mineral Resource Estimate for the Victoria Nickel Sulphide Polymetallic Deposit. The resource outlines 125 million tonnes grading 0.15% nickel equivalent (NiEq) — approximately 413 million pounds of contained NiEq within a 2.5-kilometre section of a 20-kilometre-long mineralized trend.

The Technical Report confirms that Victoria remains open along strike and at depth, with drilling extending to 320 metres below surface. The open-pit model features a strip ratio of less than 1:1, indicating potential for efficient extraction. Hosted within interlayered ultramafic and black-shale units, the deposit also contains cobalt, copper, zinc, and precious-metal credits, providing exposure to multiple critical-mineral markets.

The report further highlights additional regional targets within the Malartic Metals Package — including the Beaupré copper discovery (stripped and sampled over 180 metres of strike), the Lac Surimau gold zone, and lithium anomalies near Victoria. Together, these prospects underscore the district-scale, multi-metal potential of the property, supported by ready access to roads, hydro power, and nearby processing infrastructure.

Strengthened Technical Foundation and Financing Momentum

Renforth’s field progress has been supported by the first tranche of its ongoing financing to advance exploration and technical programs across both Parbec and Victoria. The company’s disciplined strategy — combining targeted fieldwork with continued resource definition — is solidifying its technical foundation and operational readiness.

At Parbec, the emphasis on surface exposure and geologic refinement is designed to convert modeled mineralization into demonstrable, near-surface ounces. At Victoria, the completion of the NI 43-101 report establishes a baseline for future economic and development studies — a critical step in defining the project’s long-term potential.

Outlook: Balanced Growth for a Changing Market

Renforth’s dual-track strategy reflects balance and foresight — advancing a proven gold asset in a world-class mining district while building exposure to the metals essential for the energy transition. Both projects benefit from road access, grid power, and proximity to established infrastructure, enabling efficient, low-impact exploration.

As work resumes in 2026, Renforth remains focused on two complementary objectives: unlocking near-surface gold value at Parbec and expanding its nickel-polymetallic footprint at Victoria. This balanced approach continues to strengthen the company’s position as a diversified Quebec-based explorer poised to benefit from both stability in precious metals and growth in the critical-minerals economy.

YOUR NEXT STEPS

Visit $RFR HUB On AGORACOM:https://agoracom.com/ir/RenforthResources

Visit $RFR 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/RenforthResources/profile

Visit $RFR Official Verified Discussion Forum On AGORACOM:https://agoracom.com/ir/RenforthResources/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visithttps://agoracom.com/terms-and-conditions

 

Quantum BioPharma Launches USD $7 Million Reward Program for Proof of Market Manipulation

Posted by Brittany McNabb at 3:58 PM on Friday, October 31st, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) has formally launched a public whistleblower reward program, offering up to USD $7 million to any individual or entity who can provide definitive, verifiable evidence that they were asked, hired, or induced to manipulate the Company’s stock.

This initiative is directly tied to Quantum’s ongoing landmark litigation, which alleges multi-year market manipulation and seeks damages exceeding USD $700 million.

✅ Anonymous submissions are accepted
✅ Confidentiality will be protected to the fullest extent permitted by law
✅ This program does NOT replace SEC or Canadian regulatory whistleblower programs — individuals may qualify for BOTH

How to Submit Information (Direct & Confidential)

[email protected]

Ineligible to Apply

  • Current officers, directors, or employees of Quantum BioPharma
  • Government officials/regulators acting in official capacity
  • Anyone who obtained information illegally or in violation of duty
  • Anyone submitting false or fabricated information

Important Legal Clarification

Rewards are not guaranteed and will only be paid if the submitted information materially contributes to a final, non-appealable legal judgment or binding settlement in the Company’s favor.

Quantum will not use any information provided until compensation terms are agreed to in writing with the whistleblower.

For full program details and FAQ, visit: QuantumBioPharma.com
This statement is issued in the interest of market integrity and shareholder protection.

Disclaimer

This Reward Program is discretionary and subject to change or withdrawal at any time without notice. Reward eligibility does not depend on whether a whistleblower testifies, awards are based on the contribution and reliability of the information. Quantum Biopharma will not direct, script, or influence any witness testimony. Rewards are not payments for testimony. Payment of any reward is contingent upon legal review, Board approval, and the successful outcome of a final, non‑appealable judgment or binding settlement of ongoing or future litigation pursued by the Quantum BioPharma at trial to which the reported information materially contributes. Nothing in this FAQ creates a contractual right to payment. This program does not replace, restrict or limit rights under the U.S. Securities and Exchange Commission (SEC) Whistleblower Program or whistleblower programs operated by Canadian regulatory authorities, and individuals remain free to report directly to the SEC and Canadian regulatory authorities.

 

363K oz Gold at Parbec + 413 M lb NiEq at Victoria – Renforth Strengthens Dual-Asset Position in Québec

Posted by Brittany McNabb at 3:46 PM on Wednesday, October 29th, 2025

A dual-track push in gold and critical minerals underscores the junior’s scale ambitions in Canada’s Abitibi mining hub.

Background and Context

Renforth Resources Inc. (CSE: RFR; OTCQB: RFHRF; FSE: 9RR) operates in Quebec’s Abitibi, one of the world’s most established mining districts. The company controls two 100%-owned cornerstone assets: the Parbec gold deposit, situated on the Cadillac Break near Agnico Eagle’s Canadian Malartic operation, and the Victoria nickel-polymetallic system within Renforth’s ~300 km² Malartic Metals Package. Two new developments move each asset a step forward: field work has begun to expose and sample gold at surface at Parbec, and Renforth has declared an initial, pit-constrained mineral resource at Victoria.

For investors tracking both bullion and the energy transition, the pairing is notable: near-surface gold on one side; nickel, copper, zinc and precious-metal credits on the other—each with road access and hydro power in a Tier-1 jurisdiction.

Parbec: Surface Program Targets a 12.2-Meter Gold Channel

Renforth has commenced stripping and chipping overburden on the Parbec deposit inside the area outlined by its May 2025 mineral resource model. The immediate target is a surface channel that graded 1.43 grams per tonne gold over 12.2 meters on the Diorite Splay, a structure interpreted to interact with the Cadillac Break. Once exposed, the team will prospect, map and sample the newly opened bedrock to confirm continuity and test for extensions.

Why this matters: bringing modeled mineralization to surface can sharpen geologic controls, refine near-surface ounces, and inform future bulk-sampling plans. Parbec mineralization starts at surface, is largely contained within a Whittle pit, and remains open along strike and at depth; the pit shell in prior modeling does not extend below ~300 meters. The property benefits from year-round road access in close proximity to the Canadian Malartic complex.

Renforth also disclosed a non-brokered financing initiative of up to C$500,000 in units priced at C$0.02 to support ongoing work programs.

Victoria: First Nickel Polymetallic Resource Establishes Scale

On the critical-minerals side, Renforth released its maiden mineral resource estimate for the Victoria system in Malartic, Quebec: 125 million tonnes grading 0.15% nickel equivalent (NiEq), pit-constrained, representing approximately 413 million pounds of NiEq in situ. The estimate is Inferred, based on ~10,000 meters of drilling across 2.5 kilometers of strike within a ~20-kilometer mineralized trend, and remains open along strike and at depth. The deepest pierce point to date is ~320 meters; modeled pit slopes are 50 degrees with a strip ratio of less than 1:1.

Victoria’s mineralization is hosted in interlayered ultramafic units carrying nickel, cobalt, platinum and palladium, and black shale horizons bearing zinc, copper, silver and gold. Up to three stacked horizons have been intersected at surface and in drilling across a package approaching 500 meters in thickness. Two potential starter-pit subsets leverage shallow geometry and nearby infrastructure.

What Stands Out: Practical Advantages, Not Just Geology

  • Tier-1 setting: Roads, hydro power and nearby processing facilities reduce logistical risk and cost.
  • Shallow geometry: Both Parbec and Victoria emphasize near-surface mineralization that can be evaluated with rapid, lower-cost surface programs.
  • Optionality: Gold exposure at Parbec alongside nickel-polymetallic exposure at Victoria provides commodity diversification.
  • Process pathway work: Prior TOMRA ore-sorting trials and early metallurgical studies at Victoria indicate potential to pre-concentrate and float sulphide minerals, an approach aimed at reducing throughput and inputs.

Executive and Technical Commentary

Today’s Initial MRE establishes Victoria as a large-scale, near-surface polymetallic nickel system in a top-tier jurisdiction,” said President and CEO Nicole Brewster. “With our land package, hydro power, roads and nearby plants we see a path to scale. Next steps include optimization of sorting and continued step-out and infill drilling ahead of a PEA.”

Vice President of Exploration Martin Demers called the resource “an important milestone to initiate economic evaluation,” adding that geophysical anomalies point to a broader footprint and that ongoing integration of data will guide targeting within what may be a larger magmatic system.

Potential Impact and Significance

At Parbec, confirming and extending surface gold in the Diorite Splay could strengthen near-surface resource confidence and inform development sequencing inside the open-pit shell. At Victoria, the first resource converts a district-scale target into a quantified asset with room to grow. Together, the updates frame a practical work program: surface stripping, mapping and sampling at Parbec; step-outs, infill drilling and process optimization at Victoria.

Challenges and Considerations

The Victoria estimate is categorized as Inferred, reflecting early-stage confidence that will require additional drilling to upgrade to Indicated and Measured levels. Economic viability has not been demonstrated, and future studies will need to address metallurgy, recoveries, capital needs, environmental permitting and market conditions. At Parbec, translating surface channels into mineable inventory depends on consistent continuity, validated grades and subsequent technical work.

Conclusion

Renforth’s latest steps advance two parallel narratives in Quebec’s Abitibi: a surface-driven gold program at Parbec aimed at sharpening near-term understanding, and a first-pass resource at Victoria that establishes scale in nickel and associated metals. With shallow geometry, road access and power, the company is aligning field work with practical development pathways in a jurisdiction built for mining.

YOUR NEXT STEPS

Visit $RFR HUB On AGORACOM:https://agoracom.com/ir/RenforthResources

Visit $RFR 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/RenforthResources/profile

Visit $RFR Official Verified Discussion Forum On AGORACOM:https://agoracom.com/ir/RenforthResources/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visithttps://agoracom.com/terms-and-conditions

 

The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Posted by Brittany McNabb at 3:39 PM on Wednesday, October 29th, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) is advancing a novel therapeutic approach to Multiple Sclerosis (MS) — one centered not on suppressing the immune system, but on targeting the underlying biology of demyelination, the core driver of neurodegeneration in MS. To understand why this approach matters, it’s critical to understand the role of the myelin sheath.

What Is the Myelin Sheath and Why Does It Matter?

The myelin sheath is a fatty, insulating layer that wraps around nerve cell axons — acting like the high-speed wiring system of the nervous system. It is produced by specialized glial cells: oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system.

Myelin’s value comes from four critical functions:

  • Insulation: Prevents electrical “leaks” in signal transmission
  • Speed: Enables saltatory conduction — signals “jump” node to node (up to 100× faster)
  • Efficiency: Reduces the energy neurons need to fire signals
  • System control: Supports cognition, movement, perception, and coordination

Without myelin, the electrical messages between brain and body slow, weaken, or misfire — leading to the symptoms widely associated with neurological disorders like MS.

What Happens in Multiple Sclerosis

In MS, the myelin sheath is progressively damaged — historically thought to be caused only by immune system attack. However, leading researchers now point to a second process at play: a degenerative component that occurs independently of immune activity.

Both pathways lead to demyelination — the loss or disruption of the myelin sheath — resulting in impaired communication between neurons.

This degradation is what produces the hallmark symptoms of MS:

  • Loss of motor coordination
  • Impaired sensory perception
  • Declining cognitive function
  • Fatigue and loss of balance

Quantum BioPharma’s Approach: Precision Neuroprotection

Unlike conventional immunosuppressive MS treatments, Lucid-MS – Quantum’s patented lead drug candidate — is not immunomodulatory.

Instead, it is designed to address demyelination at the biological level, advancing a neuroprotective strategy that could complement, rather than compete with, existing immune-focused treatments.

Lucid-MS has completed successful Phase 1 human safety trials, with no serious adverse events reported. Multiple animal studies have demonstrated significant activity relevant to demyelination biology, providing additional confidence as Quantum advances toward a Phase 2 clinical trial in people with MS.

A Thoughtful, Science-Driven Evolution in MS Treatment Strategy

The global MS treatment market is heavily concentrated on slowing immune system attack. Quantum BioPharma is moving deeper — focusing on the root mechanisms of nerve damage itself.

Its approach signals an evolution in neuroscience:

  • From suppression → to protection 
  • From reaction → to resilience 
  • From slowing disease → to targeting its biological engine 

Looking Ahead

Quantum BioPharma is positioning Lucid-MS within the growing global focus on regenerative and neuroprotective medicine. As regulatory preparation accelerates, the company continues to emphasize precision science, data integrity, and clinical depth — not speculation.

For official clinical progress updates, visit: www.QuantumBioPharma.com

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

 

Kidoz Redefines Privacy-First AdTech as Global Industry Forecast to Approach $2.5 Trillion

Posted by Brittany McNabb at 4:27 PM on Tuesday, October 28th, 2025

In a digital economy where the global AdTech market is projected to surpass USD 2.5 trillion by 2032, one company is quietly redefining what it means to advertise safely and effectively—Kidoz Inc. (TSXV: KDOZ | OTCQB: KDOZF).

A Scalable AdTech Platform for the Modern Era

Kidoz operates a global, privacy-first advertising network built for the new digital reality: one where regulations, compliance, and user protection are non-negotiable. Its proprietary Kidoz Safe Ad Network and Prado SDK enable contextual, data-free campaigns that reach audiences worldwide—spanning children, teens, and families—without sacrificing performance or compliance.

The company’s technology powers high-engagement mobile campaigns across more than 60 countries, supporting a billion-plus active gamers and app users. This scale has translated into measurable results, with Kidoz reporting record first-half 2025 revenue of USD $5.17 million, a 21% year-over-year increase, and over CAD $57 million in cumulative revenue over the past three years.

Riding the AdTech Expansion Wave

Global AdTech is growing fast—driven by AI, programmatic automation, and the surge in mobile engagement. As advertisers seek ways to comply with GDPR, COPPA, and new privacy acts worldwide, Kidoz stands out as one of the few networks fully aligned with these requirements from inception.

With AI-driven contextual targeting and a real-time campaign engine, Kidoz offers a blueprint for how digital marketing can evolve without intrusive data collection. Its model fits perfectly within an industry that’s moving toward transparency, accountability, and measurable ROI.

Innovation and Strategic Growth

Behind Kidoz’s success is a commitment to constant reinvestment. In 2025, R&D spending rose 48% year-over-year, while marketing surged 95% as the company expanded global awareness. Its platform enhancements—including the proprietary Kite IQ AI engine—enable smarter ad matching, delivering relevant experiences to users while maintaining full compliance.

These strategic investments ensure Kidoz remains competitive against giants in the USD 81 billion mobile gaming ad sector, where immersive formats and interactivity are defining the next frontier of engagement.

The Power of Privacy-First Design

Regulatory pressure has become one of the strongest tailwinds in digital advertising. Global frameworks such as GDPR and CCPA demand that companies handle user data responsibly—or face steep penalties. Kidoz’s advantage lies in the fact that its systems were purpose-built for compliance.

Its infrastructure is Google-certified, Apple-approved, and among the first to align with the EU AI Act. This foundation not only minimizes risk for advertisers but also offers a scalable path to growth in sectors where user trust is paramount.

Positioning for the Next Chapter

After years of disciplined execution, Kidoz is evolving from category pioneer to category leader. It now serves as a full-stack AdTech company, offering supply-side, demand-side, and ad-exchange solutions through a unified platform.

As global ad spend continues to shift toward mobile and contextual formats, Kidoz’s privacy-first ecosystem positions it squarely within the fastest-growing segments of the AdTech market.

Bottom line:
Kidoz Inc. represents the next generation of advertising technology—one built not on user tracking, but on intelligence, integrity, and innovation. In a USD 2.5 trillion industry racing toward automation and accountability, Kidoz stands out as a company built for the future of digital engagement.

https://www.fortunebusinessinsights.com/adtech-market-110325

 

Visit $KDOZ HUB On AGORACOM: https://agoracom.com/ir/Kidoz

Visit $KDOZ 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Kidoz/profile

Visit $KDOZ Official Verified Discussion Forum On AGORACOM:https://agoracom.com/ir/Kidoz/forums/discussion

Watch $KDOZ Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

 

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

Draganfly Secures U.S. Army Contract and Expands Defense Presence

Posted by Brittany McNabb at 11:16 AM on Monday, October 27th, 2025

A Strengthening Role in U.S. Defense Innovation

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A), a leading developer of unmanned aerial systems (UAS) and integrated drone solutions, is expanding its presence within the U.S. defense sector through a strategic partnership with Global Ordnance, a U.S. Defense Logistics Agency (DLA) prime contractor.

Under the agreement, Global Ordnance will serve as Draganfly’s U.S. defense partner for its line of drone platforms and related technologies. The collaboration will coordinate logistics, manufacturing, and deployment to accelerate defense adoption and strengthen North American supply-chain resilience.

U.S. Army Contract for Flex FPV Drone Systems
In September 2025, Draganfly announced an initial order from the U.S. Army for its Flex FPV (First Person View) drone systems. These drones are designed for high-performance operational use, enhancing agility, situational awareness, and field readiness.

The program includes support for embedded manufacturing at overseas U.S. Forces facilities, a model intended to shorten logistics timelines, improve sustainment, and ensure continuous operational capability. Draganfly will also provide training on flight operations, assembly, and maintenance, all within NDAA-compliant production standards.

A Strategic Partnership With Global Ordnance
Global Ordnance, headquartered in Florida with subsidiaries including Global Military Products and Mountain Horse LLC, brings extensive experience supporting U.S. and allied forces through logistics, program management, and tactical equipment supply.

The partnership combines Global Ordnance’s defense infrastructure with Draganfly’s proven UAV expertise to deliver mission-specific drone systems for intelligence, surveillance, reconnaissance, logistics, and tactical operations. Together, the companies will focus on scalability, secure manufacturing, and rapid-response capabilities.

Meeting the Growing Demand for Secure Drone Solutions
Global defense markets are rapidly transitioning toward secure, modular, and domestically produced UAS platforms. In the U.S., current policy emphasizes rapid procurement and the strengthening of compliant, homegrown supply chains.

Draganfly’s technology portfolio and strategic alliances align with this shift—positioning the company as a trusted North American supplier capable of supporting defense modernization efforts with adaptable, mission-driven platforms.

Leadership Perspective 

“By embedding manufacturing, training, and sustainment within U.S. Forces operations, we’re advancing readiness and resilience,” said Cameron Chell, Draganfly’s Chief Executive Officer. “Our goal is to ensure that personnel have mission-ready drone technology exactly where and when it’s needed.”

Advancing the Future of Defense Technology
With the U.S. Army’s adoption of the Flex FPV platform and the Global Ordnance partnership now in place, Draganfly is emerging as a credible North American leader in secure, mission-adaptive drone systems. These initiatives reflect the company’s continued commitment to supporting national security objectives through innovation, compliance, and operational excellence.

 

YOUR NEXT STEPS

Visit $DPRO HUB On AGORACOM:http:// https://agoracom.com/ir/Draganfly 

Visit $DPRO 5 Minute Research Profile On AGORACOM:http:// https://agoracom.com/ir/Draganfly/profile

Visit $DPRO Official Verified Discussion Forum On AGORACOM:http:// https://agoracom.com/ir/Draganfly/forums/discussion

Watch $DPRO Videos On AGORACOM YouTube Channel:

https://www.youtube.com/playlist?list=PLfL457LW0vdIXvNVrqwDRK0Pe8i_bAUzr

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit http://  https://agoracom.com/terms-and-conditions

BEYOND THE MIC: PyroGenesis CEO Commits Up To $4 Million in Fresh Financing – Here’s Why That Matters

Posted by Brittany McNabb at 5:31 PM on Tuesday, October 21st, 2025

PyroGenesis Inc. (TSX: PYR; OTCQX: PYRGF; FRA: 8PY1) isn’t your typical micro-cap industrial. The Montreal-based company has spent three decades building a portfolio of all-electric plasma technologies used in heavy industry and defense—ranging from plasma torches and waste destruction systems to titanium powders for additive manufacturing. 

In a new interview, President & CEO P. Peter Pascali detailed a financing move that normally wouldn’t warrant headlines: a non-brokered private placement. What elevates this one is simple—he plans to personally invest roughly up to $4 million. The conversation offers investors a clear window into the “why,” the mechanics of the raise, and how management is positioning PyroGenesis against choppy macro currents.

The Raise, Explained: Two Unit Structures, One Message

The placement is split into two unit groups—a structure driven by TSX rules that limit insider participation over a six-month window:

  • Unit Group A (CEO tranche):
    ~6.67 million units at $0.63 each; each unit includes one common share and one warrant exercisable at $0.28 for 48 months.
    Intent: Mr. Pascali expects to subscribe for most or all of this group.
  • Unit Group B (general tranche):
    4 million units at $0.20 each; each unit includes one common share and one warrant exercisable at $0.40 for 24 months.

Both groups may close in up to three tranches and carry the standard four-months-and-a-day hold.

Investor takeaway: the CEO is committing significant personal capital on terms that require future execution to pay off.

Why Now? A Candid View From the Corner Office

Pascali’s rationale blends conviction with pragmatism:

  • Alignment by design. He is already the largest shareholder, and has invested more than $13 million in recent years (and has provided short-term loans when needed
  • Execution. Management points to a previously disclosed ~$50–51 million backlog and named collaborations in Europe (Constellium, Norsk Hydro, GE). European customers reassessed broader plans as their economies experienced volatility at different times, but PyroGenesis continued to innovate, sign new contracts, and prepare for the eventual start of the projects associated to these major collaborations.
  • Geographic momentum. The **Middle East—particularly Saudi Arabia—**is emerging as a growth lane, with leadership pushing industrial modernization, localization, and advanced manufacturing (including 3D printing). PyroGenesis already manufactures key systems in the U.S. when needed, which can blunt tariff effects and streamline deliveries.

Strategy in Plain English: What PyroGenesis Actually Does

PyroGenesis develops and commercializes ultra-high-temperature, all-electric plasma technologies that help heavy industry:

  • Replace fossil-fuel burners with plasma torches in high-temp industrial processes.
  • Convert problematic waste into usable by-products or safely destroy it.
  • Produce advanced materials, including critical minerals such as titanium powders for 3D printing.

These are factory-floor solutions, not lab concepts. The company’s systems have been adopted by conservative, blue-chip operators precisely because they target efficiency, cost, reliability, emissions, and throughput—the metrics that matter to plant managers and CFOs alike.

What’s Different About This Moment

Capital discipline and access. In a market where many micro-caps face higher rates, sticky inflation, and slower funding, PyroGenesis can partially self-fund growth through insider participation while it executes on signed work.

Operational resilience. The company builds in both Canada and the U.S. to satisfy customer or policy requirements and actively monitors supplier health to reduce tariff and supply-chain risk.

Selective innovation. The team prioritizes projects with repeat-order potential and credible paths to scale—“no Hail Marys,” as Pascali puts it. That philosophy underpins a strategy designed for recurring orders rather than one-off wins.

Risks, Put Straight

No leader sugarcoated the macro picture. The CEO flagged:

  • Market volatility that seemingly changes weekly.
  • Tariffs that impact customers’ bottom lines, even when PyroGenesis itself can manufacture locally and in the U.S. to stay relatively free of tariff impact.
  • Working-capital timing, especially where large industrial clients phase payments.

The counterweight: a 34 year history of navigating shocks, a diversified customer base (mostly in Europe and the Middle East), strong backlog, and the CEO’s capital at work.

Why Investors Are Paying Attention

For current and prospective shareholders, several points stand out:

  • Skin in the game: An up to ~$4 million personal commitment from the CEO—on tougher terms
  • Industrial credibility: Deployed systems in demanding environments (on land and at sea), across 22 countries, and long-term relationships with leading metals manufacturers.
  • Path to scale: A backlog that underwrites near-term activity, plus growth vectors in Europe, North America, and the Gulf.
  • Constant Innovation: as an example, the company has increased the power of its plasma torches 20X in 5 years, from 900kW to 20MW, while improving efficiency – widening the addressable market at both the higher power (top) and lower cost (bottom) ends.

The Bottom Line

PyroGenesis is not a concept story; it’s a commercialization story. The private placement—especially the CEO’s tranche—won’t solve every macro headwind, but it does two important things: it fortifies working capital without bank leverage, and it tightens alignment between leadership and shareholders at a pivotal stage.

As Pascali put it, the decision is ultimately judged by execution. With a $50M+ backlog, marquee industrial customers, and growing demand for electrified, cleaner high-heat processes across many different heavy industries, the company has tangible levers to pull. In a market that rewards focus and resilience, PyroGenesis is making a case that it has both.

https://agoracom.com/ir/PyroGenesisCanada/forums/discussion/topics/813951-VIDEO—PyroGenesis-CEO-Invests-Big%3A-%244-Million-of-His-Own-Money/messages/2446072

 

This Small Cap AI Company Is Building Toward the Deloitte of the AI + Web3 Era

Posted by Brittany McNabb at 3:56 PM on Thursday, October 16th, 2025

A RARE COMEBACK STORY

In a market where most halted small-cap companies never return, Fobi AI has defied expectations. Under a cease-trade order since November 2024, the company didn’t fade into obscurity—the company reported nearly $3 million in 2024 revenue, including approximately $2.2 million from the sale of its German subsidiary. As CEO Rob Anson put it: “Most companies would have folded under these circumstances. We fought through every obstacle legal, financial, and market-driven and we’re coming back stronger than ever.”

FROM SURVIVAL TO STRATEGY

Fobi turned a year of constraint into a year of transformation: Consolidated operations with an annual run rate under $1.3M, enabling scale with fewer than 10 employees Redirected capital from the Passcreator sale into next-gen AI-powered wallet platforms Positioned itself as a lean, execution-first company with live products in the market

ENTERING A MULTI-BILLION-DOLLAR ARENA

The company isn’t merely returning, it’s relaunching with sharper focus. Fobi’s ambition is to become the “Deloitte of the AI + Web3 era,” offering enterprises not just strategy, but real-time implementation through integrated wallets, identity verification, and automation platforms. With applications across stadiums, airports, healthcare, and finance, the addressable market spans multiple sectors.

WHY THIS MATTERS FOR INVESTORS

Clear Market Fit: Enterprise clients need AI integration that traditional consultants can’t deliver Execution Edge: Products are live, scalable, and already generating client interest

LOOKING AHEAD

Fobi’s comeback is more than a return to trading—it is a reset. With tangible revenues, streamlined operations, and a future-focused product suite, the company is positioning itself as one of the rare small-cap survivors with the potential to thrive in the AI and Web3 economy. For investors, this represents a strategic reset rather than just a recovery, as the company builds toward its next growth phase.

This Small Cap Company’s CEO Is Investing Another $4,000,000 of His Own Money

Posted by Brittany McNabb at 3:53 PM on Thursday, October 16th, 2025

LEADERSHIP WITH SKIN IN THE GAME

In an environment where CEOs of public companies are often urged to “show leadership” by investing personally, PyroGenesis (TSX: PYR | OTCQX: PYRGF) is setting a rare benchmark for a small or micro-cap company. In this interview, CEO Peter Pascali discusses why he is committing an additional $4 million of his own capital to support PyroGenesis — the leader in innovating for ultra-high temperature processes and engineering, and a technology provider to heavy industry & defense.

This isn’t a symbolic gesture. It’s the latest installment in a personal commitment that now exceeds $19 million invested into the company, underscoring both confidence and alignment with shareholders.

CUSTOMER VALIDATION AT THE HIGHEST LEVEL

PyroGenesis’ technologies aren’t theoretical; they are deployed in some of the world’s most demanding environments. For example, its plasma arc waste destruction systems have been installed on two U.S. Navy aircraft carriers, the USS Gerald R. Ford and USS John F. Kennedy, with two more systems to follow as the additional ships’ construction is completed — a testament to the company’s ability to pass the most stringent procurement tests.

Major industrial players such as Norsk Hydro, Constellium, and GE Vernova in Europe have publicly announced projects or relationships with PyroGenesis, signaling acceptance by highly selective partners.

“I’ve seen hundreds of companies, maybe thousands, in my career,” says Pascali. “I’ve not seen one like PyroGenesis. The technology is thrilling, the adoption is real, and even in today’s market we’ve built a backlog of signed contracts around $50 million.”

STRATEGIC POSITIONING IN A VARIETY OF MARKETS

European customers aside, PyroGenesis is building momentum in the Middle East — particularly Saudi Arabia — where national leaders are investing heavily to diversify away from oil. From advanced manufacturing, to aluminum production, to 3D printing, PyroGenesis’ portfolio aligns with the region’s push to onshore high-tech production and accelerate industrial transformation.

This geographic diversification also helps buffer against economic or supply chain challenges that may face various regions, giving PyroGenesis flexibility to manufacture in North America or abroad depending on customer needs.

OUTLOOK: A UNIQUE SMALL-CAP OPPORTUNITY

PyroGenesis is navigating the same capital and interest-rate headwinds facing many small and micro-caps — but with a critical difference: a CEO who repeatedly steps up as the largest investor, a growing range of validated technologies, and a diversified global market strategy. For investors seeking a small cap company with real technologies, real and prominent customers, and leadership fully aligned with shareholder interests, this interview offers an unfiltered look at a rare story.

Watch the full discussion to see why PyroGenesis’ CEO believes the company continues to be well positioned — and why he’s backing that belief with millions of his own dollars.